Sumiko Okubo

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

Sumiko Okubo, Junichi Kurebayashi, Takemi Otsuki et al. · British Journal of Cancer · 2004 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells

Junichi Kurebayashi, Sumiko Okubo, Yutaka Yamamoto et al. · Cancer Chemotherapy and Pharmacology · 2006 · 54 citations

Medicine, Oncology, Pharmacology +14

Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.

Junichi Kurebayashi, Yutaka Yamamoto, Masafumi Kurosumi et al. · PubMed · 2006 · 37 citations

Medicine, Cancer Biology, Oncology +17

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Hibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka et al. · Lung Cancer · 2019 · 31 citations

Medicine, Oncology, Pharmacokinetics +12

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D. DiNardo et al. · Japanese Journal of Clinical Oncology · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacology +9